Better Patient Care Through Innovation

 

AVAILABLE NOW

INSYS is proud to announce the first and only liquid dronabinol, SYNDROS®, is now available by prescription.

Read More

About INSYS

Our vision is to improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs.

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

Recent News

INSYS Therapeutics to Report Third Quarter 2017 Results on Nov. 2

Recent News

INSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit

Recent News

INSYS Therapeutics Extends ‘Compassionate Use’ Studies of Cannabidiol (CBD) for Refractory Pediatric Epilepsy

Recent News

INSYS Therapeutics to Report Third Quarter 2017 Results on Nov. 2

Recent News

INSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit

Recent News

INSYS Therapeutics Extends ‘Compassionate Use’ Studies of Cannabidiol (CBD) for Refractory Pediatric Epilepsy